Experiences w/ & Attitudes Towards Immune Chckpt Inhibitors in NSCLC Patients Single Center Survey Based Study

Part of paid clinical trials in Los Angeles, California.

Sponsor
University of Southern California
Study ID
NCT07339254
Status
Recruiting
Apply to this trial

Conditions

  • Lung Non-Small Cell Carcinoma

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Non-Interventional Study — OTHER
    Non-interventional study

Study Details

This study evaluates patient satisfaction with receiving intravenous (IV) and/or subcutaneous (SC) immunotherapy and to assess patient preference for IV immunotherapy administration versus SC immunotherapy administration either at the hospital or at home.

Key Dates

Start date
Mar 12, 2026
Status verified
Mar 2026
Primary completion
Mar 12, 2027
Completion
Mar 12, 2028

Study Design

Enrollment
40 participants (estimated)

Arms

  • Arm: Observational
    Patients complete surveys on study.

Primary Outcome Measure

Strength of patient perception of Intravenous (IV) Immune Checkpoint Inhibitor (ICI) therapy [ Time Frame: At Baseline through study completion, up to 1 year. ]

Locations (2)

FacilityCityStateZIPSite coordinators
Los Angeles General Medical CenterLos AngelesCalifornia90033
Sandy Tran
[email protected]
323-865-3000
Robert Hsu (PRINCIPAL_INVESTIGATOR)
USC / Norris Comprehensive Cancer CenterLos AngelesCalifornia90033
Sandy Tran
[email protected]
323-865-3000
Robert Hsu (PRINCIPAL_INVESTIGATOR)

Find similar trials in Los Angeles, CA

By research site
Los Angeles General Medical Center· Los Angeles, CAUSC / Norris Comprehensive Cancer Center· Los Angeles, CA

Related Studies